Jason Watt, MD
Family Medicine · Jensen Beach, FLNPI 1487821641
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 78 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 78 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$383
- Indivior Inc.$219
- Neurocrine Biosciences, Inc.$214
- Novo Nordisk$203
- Gilead$115
- Lundbeck LLC$75
- plus $695 from 22 others
Across 3 payments — averaging $32,466 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$97K
What the payments were for
- Food & beverage$1,903100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $383 |
| Indivior Inc. | 8 | $219 |
| Neurocrine Biosciences, Inc. | 6 | $214 |
| Novo Nordisk | 7 | $203 |
| Gilead | 5 | $115 |
| Lundbeck LLC | 4 | $75 |
| Amgen | 3 | $65 |
| Xeris Pharmaceuticals, Inc. | 3 | $62 |
| GSK | 3 | $61 |
| AstraZeneca | 2 | $53 |
| Lilly USA, LLC | 3 | $50 |
| Mylan Specialty L.p. | 2 | $45 |
| Otsuka America Pharmaceutical, Inc. | 2 | $44 |
| SK Life Science, Inc. | 1 | $33 |
| Alkermes, Inc. | 2 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $23 |
| Viatris Specialty LLC | 1 | $22 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Braeburn Inc. | 1 | $21 |
| Abbott | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Orexo US, Inc. | 1 | $14 |
| Cipher Pharmaceuticals US LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,903 in reported general payments places this provider in the 75th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 698 | $224,149 |
| IngrezzaValbenazine Tosylate | 16 | $62,388 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $45,113 |
| OzempicSemaglutide | 32 | $36,291 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 47 | $29,695 |
| OtezlaApremilast | 14 | $27,335 |
| JardianceEmpagliflozin | 69 | $25,922 |
| XareltoRivaroxaban | 72 | $23,724 |
| YupelriRevefenacin | 15 | $22,490 |
| LinzessLinaclotide | 22 | $19,621 |
| TrulicityDulaglutide | 17 | $17,475 |
| RexultiBrexpiprazole | 14 | $16,348 |
| Atorvastatin Calcium | 775 | $14,261 |
| JanuviaSitagliptin Phosphate | 44 | $14,133 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 41 | $13,498 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Arexvy, Anoro Ellipta, Incruse Ellipta | $61 | $65,582144 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $214 | $62,38816 claims |
| GileadBiktarvy | $115 | $45,11311 claims |
| Novo NordiskOzempic | $203 | $36,29132 claims |
| Johnson & JohnsonXarelto, Procrit | $22 | $31,21995 claims |
| AbbVieLinzess, Vraylar | $383 | $30,29835 claims |
| AmgenOtezla | $65 | $27,33514 claims |
| Mylan Specialty L.p.Yupelri | $45 | $22,49015 claims |
| AstraZenecaBrilinta, Farxiga, Symbicort | $53 | $21,44056 claims |
| Lilly USA, LLCTrulicity | $50 | $17,47517 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $44 | $16,34814 claims |
| Orexo US, Inc.Zubsolv | $14 | $7,06112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Jensen Beach
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.